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Abstract
We present two deep generative models based on Variational Autoencoders to
improve the accuracy of drug response prediction. Our models, Perturbation Variational
Autoencoder and its semi-supervised extension, Drug Response Variational Autoencoder
(Dr.VAE), learn latent representation of the underlying gene states before and after
drug application that depend on: (i) drug-induced biological change of each gene and
(ii) overall treatment response outcome. Our VAE-based models outperform the current
published benchmarks in the field by anywhere from 3 to 11% AUROC and 2 to 30%
AUPR. In addition, we found that better reconstruction accuracy does not necessarily
lead to improvement in classification accuracy and that jointly trained models perform
better than models that minimize reconstruction error independently.
1 Introduction
Despite tremendous advances in the pharmaceutical industry, many patients worldwide do
not respond to the first medication they are prescribed. Personalized medicine, an approach
that uses patients’ own genomic data, promises to tailor the treatment program to increase
the probability of positive response. That idea is great, but to build powerful predictive
models, we need training data. The space of all possible treatments and their combinations
for a given condition is enormous and the heterogeneity of patients with complex diseases
is high. Thus, while much data has been collected, it is sparsely and inefficiently sampled
making it a very hard learning problem.
In the last decade there have been several public releases of high throughput drug screening
in cell lines. Cancer cell lines are cells taken from a patient’s tumor that are “immortalized”,
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i.e. modified to divide indefinitely. The greatest advantage of cell lines is that it is relatively
inexpensive to test them with thousands of drugs providing a rich basis for learning predictive
models. This screening task was undertaken by several large consortia and pharmaceutical
companies resulting in public datasets of various sizes, e.g. Genomics of Drug Sensitivity
in Cancer (GDSC) with 138 drugs (Yang et al., 2013) tested on 700 cancer cell lines, and
the Cancer Cell Line Encyclopedia (CCLE) (Barretina et al., 2012) with 24 drugs tested on
a panel of >1000 cell lines. The availability of these datasets spurred the development of
predictive models. Jang et al. (2014) compared seven standard machine learning approaches
and identified ridge and elastic net regressions as the best performers with an average AUC
of ∼0.79 across 24 compounds from the CCLE dataset and ∼0.75 across 138 compounds from
the GDSC dataset.
In addition, there is a perturbation database containing over 16,000 experiments showing
how the expression of 1000 genes changed in response to a drug (gene expression is recorded
before and after drug application) (Duan et al., 2014). This information allows for the
assessment of biological change due to treating the cancer cells with drugs. Combining
response and perturbation data is expected to ultimately yield a better and more biologically
relevant model of drug response, though likely more experiments will be needed, since there
are only a few drugs tested in each cell line.
In this paper we present two deep generative models Perturbation Variational Autoencoder
and its semi-supervised extension, Drug Response Variational Autoencoder (Dr.VAE), that
learn latent representation of the underlying gene states before and after drug application
that depend on both the cell line’s overall response to the drug and the biological change of
each of the landmark genes. We are building on VAEs ability to leverage expressiveness of
deep neural networks for Bayesian learning and inference (Kingma et al., 2014). In addition,
as Bayesian models they are more adept for the task when very little data is present, which is
the case in our drug response prediction problem. To fit our model we use a combination of
Stochastic Gradient Variational Bayes (Kingma and Welling, 2013) and Inverse Autoregressive
Flow (Kingma et al., 2016), a recently introduced type of Normalizing Flow (Rezende and
Mohamed, 2015).
We tested our methods on 19 drugs for which both perturbation and drug response data
was available. Both Dr.VAE and Semi-Supervised VAE outperform the current published
benchmark models (Jang et al., 2014) in the field by anywhere from 3 to 11% AUROC
and 2 to 30% AUPR. Our analysis of this problem and of the model performance shows
the difficulty of fitting sparsely and inefficiently sampled high dimensional data, but at the
same time illustrates the flexibility and potential improvement over the currently available
state-of-the-art models for drug response prediction problem.
2 Methods
We propose two models. First, we discuss an approach for modeling drug perturbation
effects, i.e. given gene expression of a cell line before the drug is applied (pre-treatment gene
expression), we are aiming to predict gene expression after the drug is applied (post-treatment
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Figure 1: Perturbation VAE: (a) Factorization of the generative distribution p, (b) Factoriza-
tion of the approximate posterior distribution q. Note, we use the generative pθz1→z2 in case
x2 is not observed.
state). To this end we propose a deep generative model, Perturbation VAE (PertVAE).
We then develop drug response prediction model, Drug Response Variational Autoencoder
(Dr.VAE), a semi-supervised extension of PertVAE, to tackle the problem of drug response
(treatment efficacy) prediction while harnessing the unsupervised information about the
particular drug from observed pre- and post-treatment gene expression perturbation pairs.
2.1 Perturbation VAE
Perturbation Variational Autoencoder (PertVAE) is an unsupervised model for drug-induced
gene expression perturbations, that embeds the data space (gene expression) in a lower
dimensional latent space. In the latent space we model the drug-induced effect as a linear
function, which is trained jointly with the embedding encoder and decoder.
We fit PertVAE on “perturbation pairs” [x1,x2] of pre-treatment and post-treatment gene
expression with shared stochastic embedding encoder qφx→z and decoder pθz→x . The original
dimension of each vector x is 903 genes. Additionally we use unpaired pre-treatment data
(with no know post-treatment state) to improve learning of the latent representation. The
graphical representation of PertVAE model is shown in Figure 1.
Joint distribution. Our Perturbation VAE models joint p(x1,x2, z1, z2), which we assume
to factorize as:
p(x1,x2, z1, z2) = p(x1|z1) · p(x2|z2) · p(z2|z1) · p(z1) (1)
Generative distribution p. Perturbation VAE’s generative process is as follows:
p(z1) = N (0, I) (2)
pθz1→z2(z2|z1) = N
(
z2|µz2 = fθ(z1),σz2 = expfθ(z1)
)
(3)
k ∈ {1, 2} : pθz→x(xk|zk) = N
(
xk|µxk = fθ(zk),σxk = expfθ(zk)
)
(4)
The parameters of these distributions are computed by functions fθ, which are neural
networks with a total set of parameters Θ. For brevity we refer to these parameters as Θ
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instead of more specific subsets θz→x or θz1→z2 when such level of detail unnecessarily clutters
the notation.
We constrain the mean function in pθz1→z2 to be a linear function fθz1→z2(z1) of the
following form:
fθz1→z2(z1) ≡ z1 +Wz1 + b (5)
withW and b initialized close to zero such that fθz1→z2(z1) starts as an identity function. We
found that together with L2 penalization this formulation improves stability and generalization
of the model.
Approximate posterior q. Depending on the type of the data, we assume the approximate
posterior q with a set of parameters φ to factorize as:
perturbation pairs: qφ(z1, z2|x1,x2) = qφx→z(z1|x1) · qφx→z(z2|x2) (6)
pre-treatment singleton: qφ(z1, z2,x2|x1) = qφx→z(z1|x1) · pθz1→z2(z2|z1) · pθz→x(x2|z2)
(7)
Analogously to the shared generative pθz→x distribution, also qφx→z(zk|xk) is shared for both
k ∈ {1, 2}. Here, instead of directly using a diagonal Gaussian as the final approximate
posterior
k ∈ {1, 2} : qφx→z(zk|xk) = N
(
zk|µzk = fφ(xk),σzk = expfφ(xk)
)
(8)
we apply two steps of “LSTM-type” Inverse Autoregressive Flow (IAF) (Kingma et al., 2016)
updates to facilitate a richer family of approximate distributions. A sample from qφx→z(zk|xk)
is then derived by two iterations of the following step:
z
(0)
k ∼ N
(
µzk = fφ(xk),σzk = exp
fφ(xk)
)
(9)
t ∈ {1, 2} : z(t)k = sigmoid(s(t)) z(t−1)k + (1− sigmoid(s(t)))m(t) (10)
The coefficients [m(t), s(t)] of the IAF are computed by a Masked Autoencoder for Distribution
Estimation (MADE) model (Germain et al., 2015):
[m(t), s(t)] = MADE(t)
(
z
(t−1)
k ,h(xk)
)
(11)
MADE is an autoregressive model, that is, j-th elements of the m(t) and s(t) vectors only
depend on up to the first j − 1 elements of z(t−1)k . Using this property, the determinant
of Jacobian of each IAF step can be computed efficiently. As each IAF step is then an
invertible function with known Jacobian determinant, it is thus possible to efficiently compute
probability of the derived sample z(t)k in the complex posterior qφx→z(zk|xk) that does not
have a parametric form (Kingma et al., 2016).
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Fitting θ and φ parameters. We jointly optimize the generative model θ and variational
φ parameters with Stochastic Gradient Variational Bayes (SGVB) (Kingma and Welling,
2013; Rezende et al., 2014) to maximize Evidence Lower Bound (ELBO) of the data:
NP∑
log p (x1,x2) +
NS∑
log p (x1) ≥ ELBOPertVAE (12)
ELBOPertVAE =
NP∑
LP (x1,x2; θ, φ) +
NS∑
LS (x1; θ, φ) (13)
which is a sum of the evidence lower bound of NP perturbation pairs and the lower bound
of NS unpaired “singleton” examples that we leverage to train the latent space Variational
Autoencoder as well. The individual per-example lower bounds LP and LS take the following
form:
LP (x1,x2; θ, φ) = Eqφ(z1,z2|x1,x2)
[
log pθ(x1,x2, z1, z2)− log qφ(z1, z2|x1,x2)
]
(14)
= Eqφ(z1|x1) [log pθ(x1|z1)]−DKL [qφ(z1|x1)||p(z1)] + (15)
+ Eqφ(z2|x2) [log pθ(x2|z2)]−DKL [qφ(z2|x2)||pθ(z2|z1)]
LS(x1; θ, φ) = Eqφ(z1|x1)
[
log pθ(x1, z1)− log qφ(z1|x1)
]
(16)
= Eqφ(z1|x1) [log pθ(x1|z1)]−DKL [qφ(z1|x1)||p(z1)]
Using SGVB it is possible to backpropagate through ELBOPertVAE and we use Adam (Kingma
and Ba, 2014) to compute gradient updates for both θ and φ parameters. As we use IAF
to model qφ(zk|xk), the Kullback–Leibler divergence DKL cannot be computed numerically
and therefore we use a Monte Carlo estimate. Additionally we follow (Kingma et al., 2016)
and allow “free bits” in DKL to mitigate the problem of overly strong prior causing the
optimization to get stuck in bad local optima.
2.2 Drug Response VAE
Analogously to Semi-Supervised VAE, we can extend our unsupervised Perturbation VAE
to a semi-supervised model by stacking a modified “M2 model” (Kingma et al., 2014). This
model can be trained jointly to model both drug-induced perturbation effects as well as
treatment response outcomes. As such we call this model Drug Response VAE (Dr.VAE).
We use similar type of data to train Dr.VAE as we use for PertVAE, however some of
the perturbation pairs and pre-treatment singletons now can have a binary outcome label
y associated with them, denoting if the drug treatment was successful or not. Schema of
Dr.VAE model is shown in Figure 2.
Joint distribution. Drug Response VAE extends Perturbation VAE to model a joint
distribution p(x1,x2, z1, z2, z3,y) factorized as:
p(x1,x2, z1, z2, z3,y) = p(x1|z1) · p(x2|z2) · p(z2|z1) · p(z1|z3,y) · p(z3) · p(y) (17)
5
x1 x2
y
z1 z2
z3
(a)
x1 x2
y
z1 z2
z3
(b)
Figure 2: Dr.VAE is semi-supervised extension of our Perturbation VAE: (a) Factorization
of the generative distribution p, (b) Factorization of the approximate posterior distribution
q. In case the post-treatment gene expression x2 is not observed, we can use the expected
posterior Eqφ(z1|x1) [pθ(z2|z1)] for z2 instead.
Generative distributions p. The individual generative distributions Dr.VAE factorizes
have the following form:
p(y) = Cat(y) (18)
p(z3) = N (0, I) (19)
pθ(z1|z3,y) = N
(
z1|µz1 = fθ(z3,y),σz1 = expfθ(z3,y)
)
(20)
pθ(z2|z1) = N
(
z2|µz2 = fθ(z1),σz2 = expfθ(z1)
)
(21)
k ∈ {1, 2} : pθ(xk|zk) = N
(
xk|µxk = fθ(zk),σxk = expfθ(zk)
)
(22)
Same way as in PertVAE, we share the “data decoder” pθ(xk|zk) among both k ∈ {1, 2}.
Approximate posterior q. Depending on the type of the data, we assume the approximate
posterior q to factorize as:
labeled pair: qφ(z1, z2, z3|x1,x2,y) = qφ(z1|x1) · qφ(z2|x2) · qφ(z3|z1,y) (23)
unlabeled pair: qφ(z1, z2, z3,y|x1,x2) = qφ(z1|x1) · qφ(z2|x2) · qφ(y|z1, z2) · qφ(z3|z1,y)
(24)
labeled singleton: qφ(z1, z2, z3,x2|x1,y) = qφ(z1|x1) · pθ(z2|z1) · pθ(x2|z2) · qφ(z3|z1,y) (25)
unlab. singleton: qφ(z1, z2, z3,x2,y|x1) = qφ(z1|x1) · pθ(z2|z1) · pθ(x2|z2)· (26)
· qφ(y|z1, z2) · qφ(z3|z1,y)
The “data encoder” k ∈ {1, 2} : qφ(zk|xk) is shared and parametrized the same way as in
PertVAE. The additional approximate posterior distributions then take the following form:
qφ(y|z1, z2) = Cat
(
y|pi = softmax(fφ(z1, z2))
)
(27)
qφ(z3|z1,y) = N
(
z3|µz3 = fφ(z1,y),σz3 = expfφ(z1,y)
)
(28)
The afford mentioned factorizations of the joint and of the posteriors also provide a recipe
for sampling and inference in the model by Monte Carlo sampling.
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Fitting θ and φ parameters. We have 4 different sets of partially observed variables,
which correspond to different types of data. Therefore there are 4 different evidence lower
bounds to optimize:
NLP labeled perturbation pairs:
∑NLP LLP (x1,x2,y; θ, φ) (29)
NUP unlabeled perturbation pairs:
∑NUP LUP (x1,x2; θ, φ) (30)
NLS labeled pre-treatment singletons:
∑NLS LLS (x1,y; θ, φ) (31)
NUS unlabeled pre-treatment singletons:
∑NUS LUS (x1; θ, φ) (32)
The sum of these 4 specific evidence lower bounds, ELBODrVAE, is the evidence lower bound
we need to maximize. We omit the derivation of these specific lower bounds in the main
manuscript since it follows the same principles as shown above for PertVAE and as shown in
the derivation of Semi-Supervised VAE (Kingma et al., 2014; Louizos et al., 2015).
Finally, we need to explicitly introduce loss of the predictive posterior log qφ(y|z1, z2) in
order for it to be trained also on labeled data. This is required as for the labeled data the
random variable y is observed and therefore the lower bounds LLP and LLS are conditioned
on y and do not contribute to fitting of qφ(y|z1, z2). Our final objective JDrVAE to maximize
is
JDrVAE = ELBODrVAE + α
NLP∑
Eqφ(z1,z2|x1,x2) [− log qφ(y = t|z1, z2)] +
+ α
NLS∑
Eqφ(z1,z2|x1) [− log qφ(y = t|z1, z2)]
(33)
3 Datasets
In our experiments we used two main data resources: (i) high-throughput screens of cancer
cell-lines including gene expression pre-treatment for all tested cell lines and drug response in
terms of cell line viability, and (ii) high-throughput screens of gene expression perturbation
effects induced by drugs in cancer cell lines.
We tested our methods on a panel of 19 drugs for which there are both response and
perturbation experiments available. These 19 drugs were also used in recent AstraZeneca-
Sanger DREAM Challenge and therefore we use it as a representative sample of anti-cancer
drugs.
3.1 Datasets of drug response in cancer cell lines
Large high-throughput screening efforts have been undertaken resulting in publicly available
datasets of cancer cell lines with post treatment cell viability at various drug concentrations.
In our experiments we utilize the Genomics of Drug Sensitivity in Cancer (GDSC) (Yang
et al., 2013) and Cancer Cell Line Encyclopedia (CCLE) (Barretina et al., 2012) datasets.
We obtained these datasets using PharmacoGx R package (Smirnov et al., 2015). As the drug
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response outcome we use binarized version of dose-response curves, which were computed by
PharmacoGx. For consistency, we use response outcome from GDSC, while we use all the
other cell lines in GDSC and CCLE not screened for response to a given drug as unlabeled
cell line examples. Summary of our pooled dataset is detailed in Supplementary Materials.
3.2 Drug-induced perturbations dataset
The Library of Network-Based Cellular Signatures (LINCS) consortium screened perturbation
effects that drugs have on gene expression of L1000 landmark genes in cancer cell lines (Duan
et al., 2014). These experiments do not measure the drug treatment efficacy, however some of
these cell lines were independently tested in GDSC for the drug response. We cross-reference
these cell lines and assign the corresponding label to their perturbation measurement.
The L1000 perturbation dataset is very sparse: for the 19 drugs, only up to 56 different
cell lines were screened. In fact, only 8 drugs have been measured in over 50 cell lines, the
remaining 19 have been measured in fewer than 20 cell lines, albeit at various concentrations
and with many biological replicates. In our results we use measurements at the highest drug
concentration and all the biological replicates of such experiments. In cross-validation of our
models we use cell-line-wise splitting so that the biological replicates for a particular cell line
are in the same data fold.
4 Results
We tested the performance of our models on three tasks: (i) drug response prediction task,
(ii) drug perturbation prediction and (iii) gene expression reconstruction from the latent
representation.
Architecture. All evaluated Variational Autoencoder -based models, our proposed models
(Dr.VAE, PertVAE) and the published models we used for comparison (VAE and Semi-
Supervised VAE (SSVAE)), use 100 stochastic latent units, i.e. all z are stochastic vectors
of length 100, and have the same architecture for the “data encoder” qφ(zk|xk) and “data
decoder” pθ(xk|zk). For the encoder, there are 903 input units corresponding to 903 landmark
genes (we exclude ∼70 genes that we could not uniquely map between data sets). The
encoder has hidden layers with 500 and 300 units from which parameters of initial Gaussian
distribution µzk and σzk are computed together with 200 hidden units on which the subsequent
Inverse Autoregressive Flow is conditioned. We use 2 steps of IAF, each with one hidden
layer of 300 units. Architecture of data decoder mirrors that of data encoder, but without
IAF. Throughout all our models we use ELU activation function (Clevert et al., 2015) and
Weight Normalization (Salimans and Kingma, 2016). We preserve various parts of the
architecture among different models to help with further analysis of what helps with the
observed performance.
For both Dr.VAE and SSVAE, the classification posteriors log qφ(y|z1, z2) and qφ(y|z1),
respectively, are linear functions with soft-max activation over two output units. In our
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implementation, we use a slight modification for Dr.VAE, for which we found that using
[z1, z2 − z1] instead of [z1, z2] as the classifier input improves the performance. Further, the
distributions pθ(z1|z3,y) and qφ(z3|z1,y) (and their equivalents in SSVAE) are parametrized
by a neural network with a single hidden layer of 100 units.
All our presented experiments are evaluated in 10-times randomized 5-fold cross-validation
and we report the average metric across these 50 data splits. The models were fitted
independently for each of the 19 drugs, but with the same hyperparameters.
4.1 Predicting drug response
We compare our models to Ridge L2 logistic regression (LR), random forest (RF), and support
vector machine with a linear kernel (SVM), following Jang et al. (2014) that found Ridge LR
to be the best overall classifier for drug response in GDSC dataset.
To assess informativeness of drug-induced perturbations for drug response prediction task
we also compare Dr.VAE to a Semi-Supervised VAE (Kingma et al., 2014). SSVAE is trained
on the same data, however without ability to model the drug effect, as the perturbation
pairs are simply presented as independent unlabeled singletons. On average, Dr.VAE is the
best performing method from all tested models ranging from 1% to 30% improvement over
the ridge logistic regression, considered state-of-the-art in the field. Over all 19 drugs, the
average improvement in performance is 8.95% for Dr.VAE compared to 8.07% of SSVAE.
The only drug where both Dr.VAE and SSVAE performed worse than Ridge LR is paclitaxel.
This is a chemotherapy drug (no specific gene target) with a much smaller sample size, thus
it appears that the simpler model has an advantage over all other models for this one.
Dr.VAE and SSVAE learn a latent representation of the data and the classifier jointly. To
understand the importance of learning a good latent embedding, we also explored the learning
paradigm where we first optimize latent representation in an unsupervised fashion and then
train the classifier using the already learnt embedding. To this end we trained an unsupervised
PertVAE on all perturbation pairs and afterwards fitted Ridge LR classifiers, one using the
PertVAE’s latent representation of pre-treatment gene expression (PertVAE+LR on Z1) and
another on the latent representation of predicted post-treatment state (PertVAE+LR on
Z2). Additionally, we compared these results to the baseline models trained on principal
component analysis (PCA) projection of the dataset to the first 100 principal components.
The third best average performance over all models was achieved by LR trained on the
latent embedding of pre-treatment gene expression learned by the PertVAE model. The
improvement is only 2.58% over Ridge LR and does not beat SSVAE or Dr.VAE on any of
the 19 drugs. Ridge LR performs better on PertVAE latent representations than on both
the observed gene expression and PCA representation with the same number of hidden units
(principal components) as PertVAE.
As the evaluation metric we use the area under precision-recall curve (AUPR) and area
under the ROC curve (in the Supplementary Materials). Performance of all models is
presented in Table 1.
9
Table 1: Cross-validated test AUPR (area under PR curve) of our Dr.VAE to SSVAE and
other classification models. Methods including PCA and PertVAE are 2-step methods: (i)
fit the unsupervised model, (ii) use latent representation to fit a standard classifier. The
performance comparison is presented as the relative change to Ridge LR classifier trained on
the pre-treatment gene expression.
drug Ridge LR △ RF △ SVM △PCA RF △PCA Ridge LR
△PCA 
SVM
△ PertVAE 
+ LR on Z1
△ PertVAE 
+ LR on Z2 △ SSVAE △ DrVAE
afatinib 0.527 -1.52% 2.28% -15.94% -4.74% -8.54% 2.09% -0.76% 13.47% 14.42%
bortezomib 0.731 -2.74% -0.68% -5.88% -1.78% -3.28% 1.50% 1.50% 4.79% 5.61%
docetaxel 0.772 -4.79% -0.91% -7.12% -4.02% -5.70% -1.94% -3.37% 1.42% 2.33%
doxorubicin 0.644 3.73% -1.71% 2.02% 2.80% -0.47% 4.97% 5.12% 7.92% 8.39%
etoposide 0.654 -2.29% -2.29% -4.13% -0.31% -1.07% 1.07% 0.92% 2.45% 3.67%
GDC-0941 0.641 -3.43% -1.56% -2.81% 1.72% -0.16% 1.72% 1.87% 2.03% 1.40%
gefitinib 0.285 1.05% 9.47% -7.72% 4.21% -0.35% 10.53% 11.23% 30.88% 32.63%
linsitinib 0.447 -5.15% -0.89% -10.51% -1.12% -2.68% 3.58% 0.45% 6.04% 5.59%
navitoclax 0.625 2.08% -5.76% -8.00% -3.20% -5.12% 2.56% 1.12% 10.08% 10.24%
NU-7441 0.306 -3.59% 1.63% -0.65% 5.56% 5.56% 4.90% 5.56% 10.46% 11.44%
olaparib 0.197 3.55% 6.60% 0.00% 5.08% 5.08% 22.84% 20.30% 30.46% 32.99%
paclitaxel 0.712 -9.83% 0.70% -8.85% -2.67% -4.49% -7.72% -9.27% -3.79% -3.37%
saracatinib 0.333 -13.51% -12.91% -21.92% -6.31% -10.21% -9.91% -11.11% 4.80% 10.51%
selumetinib 0.48 3.75% -1.04% -10.42% 5.83% 4.17% 6.88% 6.67% 16.04% 16.04%
SN-38   0.733 -3.14% -0.95% -4.91% -1.91% -2.05% 0.00% -0.41% 2.73% 3.27%
temsirolimus 0.721 -2.50% -1.80% -5.83% 1.66% 0.69% 0.28% -0.14% 4.72% 4.72%
tipifarnib 0.697 -3.59% -1.29% -5.16% -0.86% 0.14% 2.30% 1.58% 1.15% 1.87%
vinorelbine 0.681 -4.41% -1.03% -5.73% -0.29% -1.76% 0.88% 0.44% 2.35% 2.64%
vorinostat 0.795 0.63% 0.25% -4.65% 1.26% -0.13% 2.52% 2.52% 5.28% 5.66%
 average 0.578 -2.40% -0.63% -6.75% 0.05% -1.60% 2.58% 1.80% 8.07% 8.95%
4.2 Reconstructing gene expression
Variational Autoencoder is an expressive non-linear model, while PCA has the best recon-
struction loss among linear models. To evaluate how well a VAE with our architecture can
model gene expression, we fitted a VAE with various number of stochastic latent variables
and compared its reconstruction to reconstructions by a PCA with equivalent number of
principal components. As the measure of reconstruction quality we used Spearman’s ρ
between reconstruction mean and the original gene expression. We plot the results in Figure 3.
The Variational Autoencoder with our encoder/decoder architecture, as used in Dr.VAE and
PertVAE, does better for small latent spaces (< 20) after which it seems to overfit compared
to PCA. We chose this architecture and 100 stochastic units as the default for all our models.
We expect our models then to have enough expressive power and capacity to not just model
gene expression but also find such a latent space that can be informative for drug response
and/or drug effect can be modeled as a stochastic linear function.
4.3 Predicting post-treatment gene expression
We trained a PertVAE for each drug independently to see how well we can predict drug
perturbation effects. That is, we optimized the ELBOPertVAE and stopped training when
perturbation prediction loss started to increase on the validation set.
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Figure 3: PCA and VAE reconstruc-
tion quality comparison for varying latent
space size.
Table 2: Perturbation VAE prediction results
with latent space size 100.
drug # cell lines ⍴ rec,pert ⍴ pred,pert p-value
olaparib 56 0.529 0.517 1
selumetinib 56 0.457 0.466 0.004
vorinostat 56 0.475 0.584 7.9E-08
bortezomib 51 0.444 0.508 1.1E-11
navitoclax 51 0.505 0.485 1
SN-38   51 0.433 0.509 3.8E-14
temsirolimus 51 0.488 0.504 0.001
tipifarnib 51 0.538 0.536 0.713
GDC-0941 19 0.488 0.494 0.361
gefitinib 19 0.545 0.541 0.795
NU-7441 19 0.502 0.502 0.548
saracatinib 19 0.517 0.514 0.682
vinorelbine 14 0.51 0.504 0.659
docetaxel 13 0.524 0.509 0.981
paclitaxel 13 0.465 0.443 1
afatinib 12 0.481 0.472 0.562
etoposide 12 0.49 0.481 0.745
doxorubicin 8 0.254 0.311 0.016
linsitinib 6 0.502 0.5 0.628
To evaluate the prediction performance we computed Spearman’s correlation ρpred,pert
between the mean of predicted gene expression distribution Eqφ(z1,z2|x1)[pθ(x2|z1)] and the
observed post-treatment gene expression in the test set. We compare this correlation
to the correlation ρrec,pert between the mean of pre-treatment reconstruction distribution
Eqφ(z1|x1)[pθ(x1|z1)] and the true post-treatment gene expression. This is done to assess
whether the drug perturbation function is in fact learning anything beyond reconstructing
pre-treatment gene expression. Note, that in the training step the “drug effect” mean function
is initialized close to identity. If PertVAE would either underfit or overfit on the training set,
we would expect ρpred,pert to be no larger than ρrec,pert. Therefore we calculate Mann-Whitney
single-sided test with the alternative hypothesis H1 = ρrec,pert < ρpred,pert on the results of our
10-times randomized 5-fold CV. The average correlation values and p-values of the statistical
test are in Table 2, showing that PertVAE can at least partially predict drug perturbations for
5 out of 8 drugs (p-value ≤ 0.001) for which the data set consists of perturbation experiments
with at least 51 unique cell lines.
5 Discussion
In our explorations of optimizing latent space, we found that doing well on reconstruction
task does not directly lead to improved classification performance. The ability of Dr.VAE to
model drug-induced perturbation effects on gene expression leads to limited improvement
in classification performance. Compared to fitted PertVAE, a Dr.VAE model trained pre-
dominantly for classification does not learn to predict perturbation effects along the way.
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However, it is the best performing classification model. This set of observations compells us
to conclude that the latent space serves a different role than simply compressing observed
gene expression. Given a very small set of samples, very heterogeneous and noisy input and
likely noisy output, the goal of the latent space is to capture the essense of the observed gene
expression that is most useful and likely biased for prediction. The original goal of our work
was to create a rich paradigm where much of the available data can be incorporated to boost
the predictive performance of drug response. We did achieve an improvement in predicting
drug response in the flexible and powerful VAE framework that we believe is the way to
model such data in the future.
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A Data sets summary
Table 3: Dataset summarization. (a) Number of labeled and unlabeled pre-treatment
singletons and perturbation pairs. In L1000 perturbation columns, the total number of
experiments including biological replicates is shown, while the number of unique cell lines is
listed in parentheses. (b) Shows split of the response-labeled samples to negative and positive
classes.
(a)
drug labeled CL unlabeled CL
afatinib 647 636 17 (3) 42 (9)
bortezomib 501 782 2 (1) 167 (50)
docetaxel 671 612 36 (3) 76 (10)
doxorubicin 646 637 10 (2) 42 (6)
etoposide 653 630 26 (2) 121 (10)
GDC-0941 636 647 41 (3) 134 (16)
gefitinib 647 636 52 (3) 138 (16)
linsitinib 646 637 5 (1) 28 (5)
navitoclax 645 638 42 (8) 127 (43)
NU-7441 643 640 24 (3) 88 (16)
olaparib 647 636 44 (8) 155 (48)
paclitaxel 338 945 0 (0) 83 (13)
saracatinib 341 942 0 (0) 171 (19)
selumetinib 617 666 41 (8) 165 (48)
SN-38   647 636 36 (8) 128 (43)
temsirolimus 647 636 44 (8) 129 (43)
tipifarnib 646 637 37 (7) 137 (44)
vinorelbine 653 630 31 (2) 139 (12)
vorinostat 647 636 44 (8) 182 (48)
CCLE ∪ GDSC L1000 perturbations
labeled 
(unique CL)
unlabeled 
(unique CL)
(b)
drug non responsers responders
afatinib 483 164
bortezomib 211 290
docetaxel 262 409
doxorubicin 248 398
etoposide 276 377
GDC-0941 255 381
gefitinib 523 124
linsitinib 409 237
navitoclax 426 219
NU-7441 465 178
olaparib 542 105
paclitaxel 136 202
saracatinib 266 75
selumetinib 395 222
SN-38 234 413
temsirolimus 269 378
tipifarnib 246 400
vinorelbine 261 392
vorinostat 220 427
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B AUROC Results
Table 4: Cross-validated test AUROC (area under ROC curve) of our Dr.VAE to SSVAE
and other standard classification models. Methods including PCA and PertVAE are two step
methods: (i) fit the unsupervised model and (ii) use latent representation to fit a standard
classifier. Performance of the compared methods is presented as the relative change to Ridge
logistic regression classifier trained directly on the pre-treatment gene expression.
drug Ridge LR △ RF △ SVM △PCA RF △PCA Ridge LR
△PCA 
SVM
△ PertVAE 
+ LR on Z1
△ PertVAE 
+ LR on Z2 △ SSVAE △ DrVAE
afatinib 0.527 -1.52% 2.28% -15.94% -4.74% -8.54% 2.09% -0.76% 13.47% 14.42%
bortezomib 0.731 -2.74% -0.68% -5.88% -1.78% -3.28% 1.50% 1.50% 4.79% 5.61%
docetaxel 0.772 -4.79% -0.91% -7.12% -4.02% -5.70% -1.94% -3.37% 1.42% 2.33%
doxorubicin 0.644 3.73% -1.71% 2.02% 2.80% -0.47% 4.97% 5.12% 7.92% 8.39%
etoposide 0.654 -2.29% -2.29% -4.13% -0.31% -1.07% 1.07% 0.92% 2.45% 3.67%
GDC-0941 0.641 -3.43% -1.56% -2.81% 1.72% -0.16% 1.72% 1.87% 2.03% 1.40%
gefitinib 0.285 1.05% 9.47% -7.72% 4.21% -0.35% 10.53% 11.23% 30.88% 32.63%
linsitinib 0.447 -5.15% -0.89% -10.51% -1.12% -2.68% 3.58% 0.45% 6.04% 5.59%
navitoclax 0.625 2.08% -5.76% -8.00% -3.20% -5.12% 2.56% 1.12% 10.08% 10.24%
NU-7441 0.306 -3.59% 1.63% -0.65% 5.56% 5.56% 4.90% 5.56% 10.46% 11.44%
olaparib 0.197 3.55% 6.60% 0.00% 5.08% 5.08% 22.84% 20.30% 30.46% 32.99%
paclitaxel 0.712 -9.83% 0.70% -8.85% -2.67% -4.49% -7.72% -9.27% -3.79% -3.37%
saracatinib 0.333 -13.51% -12.91% -21.92% -6.31% -10.21% -9.91% -11.11% 4.80% 10.51%
selumetinib 0.48 3.75% -1.04% -10.42% 5.83% 4.17% 6.88% 6.67% 16.04% 16.04%
SN-38   0.733 -3.14% -0.95% -4.91% -1.91% -2.05% 0.00% -0.41% 2.73% 3.27%
temsirolimus 0.721 -2.50% -1.80% -5.83% 1.66% 0.69% 0.28% -0.14% 4.72% 4.72%
tipifarnib 0.697 -3.59% -1.29% -5.16% -0.86% 0.14% 2.30% 1.58% 1.15% 1.87%
vinorelbine 0.681 -4.41% -1.03% -5.73% -0.29% -1.76% 0.88% 0.44% 2.35% 2.64%
vorinostat 0.795 0.63% 0.25% -4.65% 1.26% -0.13% 2.52% 2.52% 5.28% 5.66%
 average 0.578 -2.40% -0.63% -6.75% 0.05% -1.60% 2.58% 1.80% 8.07% 8.95%
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